ZIMMER BIOMET TO ACQUIRE MONOGRAM TECHNOLOGIES

Zimmer Biomet has entered into a definitive agreement to acquire Monogram Technologies in a deal valued at approximately $168 million enterprise value, with additional contingent value rights that could bring the total over $12 per share if development and revenue milestones are met through 2030. The acquisition builds on Monogram's FDA- cleared CT-based, semi-autonomous robotic knee arthroplasty system, slated for commercialization in early 2027. Monogram's system integrates preoperative CT imaging and real-time navigation with partial robotic assistance during total knee replacement surgeries. The technology reduces manual alignment variability and enhances precision. Zimmer Biomet plans to integrate Monogram's technology into its flagship ROSA robotics platform, thereby offering a pathway to fully autonomous surgical procedures. Zimmer Biomet's existing portfolio includes imageless robotics, mixed reality navigation, and AI-enhanced surgical planning tools. The Monogram acquisition reinforces its trajectory toward more autonomous orthopedic surgery and allows the company to position as a leader in robotic knee, hip, and shoulder replacement solutions globally. ROSA Knee with OptimiZe, ROSA Posterior Hip, and ROSA Shoulder commercialization programs are underway, targeting rollout by 2027. Industry observers note that combining Zimmer Biomet's implant business with Monogram's robotic platform could significantly elevate surgical outcomes and address surgeon preference across manual, semi-autonomous, and future fully autonomous modalities. The acquisition is expected to be neutral to earnings through 2027 and accretive in 2028 and beyond. About Zimmer Biomet Zimmer Biomet is a global orthopedics and medical technology company headquartered in Indiana, specializing in implants, surgical robotics, and enabling technologies for joint replacement surgeries. For more information, visit zimmerbiomet.com.